2026-06-30T03:03:57Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/232992024-11-28T20:35:52Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Montaño, Juan José author Barceló, Antoni author Franch, Paula author Galceran, Jaume author Ameijide, Alberto author Pons De Ves, Jaime author Ramos Monserrat, Maria 2024-09-18T06:43:55Z 2024-09-18T06:43:55Z 2021-10-24 Montaño JJ, Barceló A, Franch P, Galceran J, Ameijide A, Pons J, et al. Prostate cancer survival by risk and other prognostic factors in mallorca, spain. Int J Environ Res Public Health. 2021;18(21). 10.3390/ijerph182111156 1660-4601 International journal of environmental research and public health http://hdl.handle.net/20.500.13003/18486 34769675 L2014205171 2-s2.0-85117502511 https://hdl.handle.net/20.500.12105/23299 719526500001 Studies about the survival of patients with prostate cancer by stage or risk of progression are scarce. The aims of this study were (1) to determine the cause-specific survival by risk in prostate cancer patients in Mallorca diagnosed in the period 2006-2011; (2) to identify the factors that explain and predict the likelihood of survival and the risk of dying from this type of cancer; and (3) to determine the distribution of prostate cancer by risk in the patients in Mallorca diagnosed in the period 2006-2011. Incident prostate cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. We collected age; date and method of diagnosis; date of follow-up or death; T, N, M and stage according to the TNM 7th edition; Gleason score; prostate-specific antigen (PSA); histology according to the International Classification of Diseases for Oncology (ICD-O) 3rd edition, comorbidities and treatments. We calculated risk in four categories: low, medium, high and very high. The end point of follow-up was 31 December 2014. Multiple imputation (MI) was performed to estimate cases with unknown risk. We identified 2921 cases. Five years after diagnosis, survival after MI was 89% globally, and was 100% for low-risk cases, 96% for medium risk, 93% for high risk and 69% for very-high-risk cases. Cases with histology other than adenocarcinoma, with high (and especially very high) risk, as well as with systemic, mixed and observation/unspecified treatments had worse prognoses. eng Prostate neoplasm Survival Stage Multiple imputation Prostate Cancer Survival by Risk and Other Prognostic Factors in Mallorca, Spain research article